Clinical Trials

Below is a listing of clinical trials conducted at MUSC Hollings Cancer Center. Use the tools in the left toolbar to refine your search. If you are interested in Early Phase/Multi Tumor trials, select the program “Phase I Unit.” Please note that cohort information for the Phase I trials changes often.

Clinical Research Group Intranet
Hold Ctrl (Cmd on Mac) to select multiple.
Protocol Title Status Docs
104160 BCC021- Phase I/II Study of Silmitasertib (CX-4945) in Combination with Chemotherapy in Children and Young Adults with Relapsed Refractory Solid Tumors OPEN TO ACCRUAL

104306 A Phase 1 Open-Label, Multicenter Study of JANX014 in Participants with Prostate Cancer OPEN TO ACCRUAL

104311 A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303) OPEN TO ACCRUAL

104396 A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS25 (RxFINE-Low) OPEN TO ACCRUAL

104354 Comparing Oral Drug Dosing Strategies in Older Patients with Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study OPEN TO ACCRUAL

104302 A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physicians Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma OPEN TO ACCRUAL

104399 Radiotherapy with Concurrent Cetuximab vs. Carboplatin and Paclitaxel in Patients with Locoregionally Advanced Head and Neck Cancer with aContraindication to Cisplatin: A Pragmatic Phase III Randomized Trial (CONCISE) OPEN TO ACCRUAL

104291 A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma OPEN TO ACCRUAL

104230 Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) OPEN TO ACCRUAL

104305 A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301) OPEN TO ACCRUAL

104199 A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults with Advanced Solid Tumors OPEN TO ACCRUAL

104246 A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1) OPEN TO ACCRUAL

104044 Neo-TILs: A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple Negative Breast Cancer (TNBC) Patients with Elevated Tumor-Infiltrating Lymphocytes (TILs) OPEN TO ACCRUAL

104359 A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma OPEN TO ACCRUAL

104233 A Phase 1, First-in-Human, Open-label, Multicenter Study of JZP898 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors OPEN TO ACCRUAL

104365 PHASE III TRIAL OF RADIOTHERAPY FOLLOWED BY ADJUVANT TEMOZOLOMIDE IN COMBINATION WITH THE IDH INHIBITOR VORASIDENIB VS. PLACEBO IN IDH-MUTATED NEWLY-DIAGNOSED GRADE 3 ASTROCYTOMAS OPEN TO ACCRUAL

104286 A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer OPEN TO ACCRUAL

104245 A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer OPEN TO ACCRUAL

104112 A Phase 3, Multi-center, Double-blind, 2-part Study in Participants with KRAS G12C-Mutant, Non-Small Cell Lung Cancer Comparing the Efficacy and Safety of Olomorasib in Combination with Standard of Care to Placebo in Combination with Standard of Care as Adjuvant Treatment after Platinum-based Chemotherapy OPEN TO ACCRUAL

104299 A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial OPEN TO ACCRUAL